texas oncology more breakthroughs. more victories
Some of our cancer centers may have important notifications found on the location page. View More Important Notifications x

A. David McCollum, M.D.

A. David McCollum, M.D. Photo

Provider Type: Physician

Board Certifications:
  • Medical Oncology


General Summary

A. David McCollum, M.D. has clinical and research interests in cancers of the gastrointestinal tract, including colon cancer, rectal cancer, esophageal and stomach cancer, and pancreatic cancer.  He is a Diplomate of the American Board of Internal Medicine with subspecialty certifications in hematology and medical oncology. Dr. McCollum served on the Board of Texas Oncology between 2007 and 2010 and is a member of the Scientific Planning Committee of Texas Oncology and the Gastrointestinal Cancers Committee of The US Oncology Network. Dr. McCollum's academic affiliations have included Instructor of Internal Medicine at U.T. Southwestern Medical School, Dallas, Texas, 1998-1999, and Instructor of Medicine at Harvard Medical School, Boston, Massachusetts, 1999-2002. He served as a member of the Gastrointestinal Cancers Research Committee at Dana Farber/Partners Cancer Care from 2000 through the spring of 2002. Upon joining Texas Oncology, P.A. in 2002, he became a member of The US Oncology Network Gastrointestinal Cancers Research Committee.


Dr. McCollum received a B.B.A. with honors from The University of Texas at Austin in 1991. He received his M.D. from The University of Southwestern Medical School in Dallas, Texas in 1995. He served as Chief Medicine Resident at U.T. Southwestern Medical Center in 1998-1999, and in 2000 he completed a Clinical Effectiveness Program at the Harvard School of Public Health in Boston, MA. He completed his clinical and research fellowships in Hematology and Medical Oncology at the Dana-Farber Cancer Institute and Partners Cancer Care Training Program (Boston, MA) in 2002. During his training at the Dana-Farber Cancer Institute in Boston, he was the recipient of the Noah T. Herndon Fellowship and the Irving W. Janock Fellowship in GI Malignancies.

Accolades & Memberships

American Medical Association, Texas Medical Association, Dallas County Medical Society, American Society of Clinical Oncology, Massachusetts Medical Society, and Alpha Omega Alpha Honor Medical Society. Recipient of a 2001 Merit Award from the American Society of Clinical Oncology for research presented at the annual meeting.


  • Phase II Trial of Docetaxel and Oxaliplatin in Patients With Advanced Gastric Cancer and/or Adenocarcinoma of the Gastroesophageal Junction

    Annals of Oncology, 2008

  • Stage III colon cancer at Baylor University Medical Center at Dallas and the Baylor Sammons Cancer Center: experience from 2000 to 2004

    Proc (Bayl Univ Med Cent), 2006

  • The Combination of Capecitabine and Thalidomide in Previously Treated, Refractory Metastatic Colorectal Cancer

    American Journal of Clinical Oncology, 2006

  • A Phase II Study of Gemcitabine Plus Zoledronic Acid in Stage IV Cancer of the Pancreas

    ASCO Gastrointestinal Cancers Symposium, 2006